Last updated July 18, 2026
Key finding
Median time to 1st redeemed glucose-lowering drug prescription was 3.9 years in the conventional group.
This study examined the genetic influence of type 2 diabetes susceptibility variants on disease progression using two treatment algorithms. It found that an intensive treatment approach reduced the time to first drug prescriptions compared to conventional treatment.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the genetic influence of type 2 diabetes susceptibility variants on disease progression using two treatment algorithms. It found that an intensive treatment approach reduced the time to first drug prescriptions compared to conventional treatment.
These findings highlight the importance of treatment strategies in managing type 2 diabetes. By demonstrating that intensive treatment can lead to earlier medication initiation, healthcare providers may consider adopting more aggressive management approaches to improve patient outcomes and potentially delay disease progression.
The effectiveness of the interventions remains unclear due to limited evidence. The study may not be generalizable to all populations with type 2 diabetes. Potential confounding factors were not fully accounted for in the analysis.
Published in
Publication details and source links for this paper.
Malene H, Kristine HA, Majken LJ, et al. Genetic Influence of Type 2 Diabetes Susceptibility Variants on Disease Progression. PLoS ONE. 2014;9(8):e104837. doi:10.1371/journal.pone.0104837
The median time to first redeemed glucose-lowering drug prescription was 3.9 years in the conventional group versus 2.5 years in the intensive group, a decrease of 1.4 years (p=0.009).
The median time to first redeemed insulin prescription was 6.0 years in the conventional group compared to 5.9 years in the intensive group, a decrease of 0.1 years (p=0.02).
Increased HbA1c and BMI were significant predictors of diabetes progression.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Multifactorial intensive treatment algorithm, Standard type 2 diabetes medication treatment, unspecified and BMI, HDL cholesterol, HbA1c, and 3 more.
This study contributes evidence to
Primary intervention
Multifactorial intensive treatment algorithm
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
12
Evidence pairs
462
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Multifactorial intensive treatment algorithm → BMI
Multifactorial intensive treatment algorithm → BMI
Multifactorial intensive treatment algorithm → HbA1c
Multifactorial intensive treatment algorithm → HbA1c
Multifactorial intensive treatment algorithm → HDL cholesterol
Multifactorial intensive treatment algorithm → HDL cholesterol
Multifactorial intensive treatment algorithm → Time to first redeemed glucose-lowering drug prescription
Multifactorial intensive treatment algorithm → Time to first redeemed glucose-lowering drug prescription
Multifactorial intensive treatment algorithm → Time to first redeemed insulin prescription
Multifactorial intensive treatment algorithm → Time to first redeemed insulin prescription
Multifactorial intensive treatment algorithm → Triglycerides
Multifactorial intensive treatment algorithm → Triglycerides
Standard type 2 diabetes medication treatment, unspecified → BMI
Standard type 2 diabetes medication treatment, unspecified → BMI
Standard type 2 diabetes medication treatment, unspecified → HbA1c
Standard type 2 diabetes medication treatment, unspecified → HbA1c
Standard type 2 diabetes medication treatment, unspecified → HDL cholesterol
Standard type 2 diabetes medication treatment, unspecified → HDL cholesterol
Standard type 2 diabetes medication treatment, unspecified → Time to first redeemed glucose-lowering drug prescription
Standard type 2 diabetes medication treatment, unspecified → Time to first redeemed glucose-lowering drug prescription
Standard type 2 diabetes medication treatment, unspecified → Time to first redeemed insulin prescription
Standard type 2 diabetes medication treatment, unspecified → Time to first redeemed insulin prescription
Standard type 2 diabetes medication treatment, unspecified → Triglycerides
Standard type 2 diabetes medication treatment, unspecified → Triglycerides
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Multifactorial intensive treatment algorithm and Body Mass Index, Multifactorial intensive treatment algorithm and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Behavioral & Lifestyle
Behavioral & Lifestyle
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Multifactorial intensive treatment algorithm
Contributes to Multifactorial intensive treatment algorithm evidence base.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Multifactorial intensive treatment algorithm appears to improve BMI.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Multifactorial intensive treatment algorithm appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Multifactorial intensive treatment algorithm appears to improve Time to first redeemed glucose-lowering drug prescription.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to first redeemed glucose-lowering drug prescription
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Multifactorial intensive treatment algorithm appears to improve Time to first redeemed insulin prescription.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to first redeemed insulin prescription
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
